Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES THIRD QUARTER RESULTS

 EATONTOWN, N.J., Nov. 18 ~PRNewswire~ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) today reported total revenues of $8.5 million for the quarter ended Sept. 30, 1992, an increase of $5.4 million or 174 percent over total revenues of $3.1 million for the same quarter of the prior year. Product sales accounted for $7.5 million compared to $2.7 million for the same period in 1991. For the nine month period ended Sept. 30 1992, revenues totalled $20.6 million representing an increase of $12.3 million or 148 percent over the prior year period revenues of $8.3 million. Product sales for the nine month periods Sept. 30, 1992 and 1991 totalled $17.8 million and $6.9 million, respectively. Sales of prescription products amounted to $12.8 million or 72 percent of total product sales, an increase of $8.0 million over the same nine month period of the prior year.
 For the third quarter Roberts reported a net loss of $2.9 million or $.20 per share on 14.6 million shares outstanding compared to a net loss for the third quarter of 1991 of $1.6 million or $.16 per share on 9.9 million shares outstanding. The net loss for the nine months ended Sept. 30, 1992 was $7.6 million compared to the net loss of $4.2 million for the nine months ended Sept. 30, 1991. Loss per share amounted to $.57 compared with $.49 in 1991.
 The company's operating expenses of $12.2 million for the quarter ended Sept. 30, 1992 were $7.5 million above the $4.7 million incurred during the comparable period in 1991 due largely to the company's continued and expended development of its late stage prescription products and increased marketing and promotional expenditures in support of the company's growing base of currently marketed products.
 In reviewing the overall financial results of the third quarter Dr. Robert A. Vukovich, chairman and CEO, stated, "As our revenue base continues to expand, we are accelerating our product development programs. This growth in revenue and enhanced product development, combined with our substantial financial resources, including $83 million in cash, places Roberts in an excellent position for both short and long term growth."
 In comparing the previous two quarters of 1992, the following overview was presented:
 -- Revenues continue to grow substantially as product sales for the third quarter increased $1.8 million or 32 percent above the second quarter of this year.
 -- The net loss for the quarter decreased 19 percent or $668,300 ($.05 per share) from $3,594,800 million or $.25 per share in the second quarter to $2,926,500 million or $.20 per share in the third quarter.
 -- On a quarter to quarter basis, operating expenses increased 8 percent; a significantly less percentage increase compared to the 21 percent increase in sales.
 -- Performance as measured as a percentage of revenue improved as the net loss for the current quarter was 34 percent of sales compared with 51 percent of sales for the second quarter.
 Roberts Pharmaceutical is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the U.S., Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough~cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
 ROBERTS PHARMACEUTICAL CORPORATION
 Summary Consolidated Financial Information
 For the third quarter ended Sept. 30, 1992
 (All amounts in thousands, except per share data, unaudited)
 BALANCE SHEET DATA
 9~30~92 12~31~91
 Assets
 Cash and marketable securities $82,520 $14,161
 Other current assets 11,930 5,600
 Other assets 57,023 24,389
 Total assets 151,473 44,150
 Liabilities & Stockholders' Equity
 Current liabilities 16,006 9,807
 Long-term debt and other liabilities 12,675 9,237
 Stockholders' equity 122,792 25,106
 Total liabilities & stockholders' equity 151,473 44,150
 OPERATING STATEMENT DATA
 Periods ended Three months Nine months
 Sept. 30 1992 1991 1992 1991
 Revenues:
 Product sales $7,534 $2,749 $17,807 $ 6,875
 Other revenue 1,015 331 2,772 1,451
 Total 8,549 3,080 20,579 8,326
 Net loss (2,927) (1,610) (7,616) (4,185)
 Net loss per common share (.20) (.16) (.57) (.49)
 Weighted average common
 shares outstanding 14,649 9,916 13,461 8,479
 -0- 11~18~92
 ~CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182~
 (RPCX)


CO: Roberts Pharmaceuticals Corporation ST: New Jersey IN: MTC SU: ERN

SH-LR -- NY054 -- 2418 11~18~92 13:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1992
Words:791
Previous Article:BURLINGTON COAT FACTORY CHAIRMAN ANNOUNCES NEW LOCATIONS
Next Article:S&K FAMOUS BRANDS ANNOUNCES RECORD SALES AND EARNINGS FOR THE THIRD QUARTER OF FISCAL 1993
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES THIRD QUARTER RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD 1992 SALES RESULTS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES RECORD SALES AND PROFITS
ROBERTS PHARMACEUTICAL CLARIFIES PREVIOUSLY ANNOUNCED 1994 FINANCIAL RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS ON 1994 AUDITED FINANCIAL RESULTS
Roberts Pharmaceutical Corporation Reports Second Quarter Results Substantially Improved From First Quarter 1996 Results
Roberts Pharmaceutical Corporation Expects Fourth Quarter 1996 Operating Results to Exceed Analyst Projections
Roberts Pharmaceutical Corporation Revises 1996 EPS Calculation to Conform with New SEC Guidelines; No Impact on Reported Net Income or Balance Sheet
Roberts Pharmaceutical Corporation Updates Third Quarter Outlook
Roberts Pharmaceutical Corporation Anticipates Reporting a Third Quarter Profit Exceeding Expectations.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters